Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kohei Shitara

Showing results (181-190 of 344) with videos related to

Pageof 35
Sort By:
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|July 24, 2020
A multicenter phase II study of TAS-114 in combination with S-1 in patients with pretreated advanced gastric cancer (EPOC1604)Akihito Kawazoe, Daisuke Takahari, Chin Keisho, et al.
Clinical Pharmacokinetics|August 14, 2025
Clinical Pharmacology Profile of the Claudin 18.2 Antibody ZolbetuximabJianning Yang, Akihiro Yamada, Kohei Shitara, et al.
Cancer Science|August 23, 2011
Association between insulin-like growth factor-1 polymorphisms and stomach cancer risk in a Japanese populationDaisuke Ennishi, Kohei Shitara, Hidemi Ito, et al.
International Journal of Clinical Oncology|June 17, 2022
Characteristics and clinical outcomes of patients with advanced gastric or gastroesophageal cancer treated in and out of randomized clinical trials of first-line immune checkpoint inhibitorsYu Aoki, Akihito Kawazoe, Yohei Kubota, et al.
ESMO Open|November 15, 2018
Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinomaSaori Mishima, Akihito Kawazoe, Hiroshi Matsumoto, et al.
JAMA Oncology|August 25, 2022
Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical TrialsHarry H Yoon, Zhaohui Jin, Oudom Kour, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|February 3, 2017
Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOGKozo Kataoka, Takahiro Kinoshita, Markus Moehler, et al.
Cancer Science|July 25, 2018
Dose-finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumorsSatoru Iwasa, Noboru Yamamoto, Kohei Shitara, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|February 10, 2020
Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G)Takako Eguchi Nakajima, Kensei Yamaguchi, Narikazu Boku, et al.
Journal for Immunotherapy of Cancer|August 16, 2019
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumorsKohei Shitara, Taroh Satoh, Satoru Iwasa, et al.
Pageof 35

Showing results (181-190 of 344) with videos related to

Sort By:
Pageof 35
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|July 24, 2020
A multicenter phase II study of TAS-114 in combination with S-1 in patients with pretreated advanced gastric cancer (EPOC1604)Akihito Kawazoe, Daisuke Takahari, Chin Keisho, et al.
Clinical Pharmacokinetics|August 14, 2025
Clinical Pharmacology Profile of the Claudin 18.2 Antibody ZolbetuximabJianning Yang, Akihiro Yamada, Kohei Shitara, et al.
Cancer Science|August 23, 2011
Association between insulin-like growth factor-1 polymorphisms and stomach cancer risk in a Japanese populationDaisuke Ennishi, Kohei Shitara, Hidemi Ito, et al.
International Journal of Clinical Oncology|June 17, 2022
Characteristics and clinical outcomes of patients with advanced gastric or gastroesophageal cancer treated in and out of randomized clinical trials of first-line immune checkpoint inhibitorsYu Aoki, Akihito Kawazoe, Yohei Kubota, et al.
ESMO Open|November 15, 2018
Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinomaSaori Mishima, Akihito Kawazoe, Hiroshi Matsumoto, et al.
JAMA Oncology|August 25, 2022
Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical TrialsHarry H Yoon, Zhaohui Jin, Oudom Kour, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|February 3, 2017
Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOGKozo Kataoka, Takahiro Kinoshita, Markus Moehler, et al.
Cancer Science|July 25, 2018
Dose-finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumorsSatoru Iwasa, Noboru Yamamoto, Kohei Shitara, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|February 10, 2020
Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G)Takako Eguchi Nakajima, Kensei Yamaguchi, Narikazu Boku, et al.
Journal for Immunotherapy of Cancer|August 16, 2019
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumorsKohei Shitara, Taroh Satoh, Satoru Iwasa, et al.
Pageof 35